Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

May 25, 2020

Conditions
Prader-Willi SyndromeHyperphagia
Interventions
DRUG

Livoletide

Daily subcutaneous injection

DRUG

Placebo

Daily subcutaneous injection

Trial Locations (37)

1200

Cliniques Universitaires Saint-Luc, Brussels

2050

Royal Prince Alfred Hospital, Camperdown

2145

The Childrens Hospital at Westmead, Westmead

3015

Erasmus University Medical Center, Rotterdam

3016

Stichting Kind en Groei, Rotterdam

3084

Austin Health, Melbourne

6009

Perth Children's Hospital, Nedlands

10032

New York Presbyterian Morgan Stanley Children's Hospital, New York

11501

Winthrop University Hospital, Mineola

21287

Johns Hopkins University, Baltimore

31059

CHU de Toulouse - Hospital Rangueil, Toulouse

35233

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

48109

University of Michigan, Ann Arbor

48903

Hospital de Cruces, Barakaldo

49100

Centre Hospitalier Universitaire d'Angers, Angers

55102

Children's Hospitals and Clinics of Minnesota-Minneapolis, Saint Paul

66160

University of Kansas Medical Center, Kansas City

69677

CHU Lyon - Hopital Femmes Mere Enfant, Bron

75013

Hospital Pitie Salpetriere, Paris

75015

Hopital Necker-Enfants Malades, Paris

75390

University of Texas Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

80045

Children's Hospital Colorado, Denver

80131

Azienda Ospedaliera Universitaria Federico II, Napoli

92123

Rady Children's Hospital - San Diego, San Diego

92868

University of California - Irvine Medical Center, Orange

98105

Seattle Children's Hospital, Seattle

02215

Boston Children's Hospital, Boston

Unknown

CHU de Toulouse - Hopital des Enfants, Toulouse

00165

Ospedale Pediatrico Bambino Gesù, Roma

03010

Hospital General Universitario de Alicante, Alicante

08950

Hospital Sant Joan de Deu, Barcelona

08208

Corporacio Sanitaria Parc Tauli - Hospital de Sabadell, Sabadell

DD1 9SY

NHS Tayside, Dundee

SW109NH

Chelsea and Westminster Hospital, London

W12 0NN

Imperial College London, London

Sponsors
All Listed Sponsors
lead

Millendo Therapeutics SAS

INDUSTRY

NCT03790865 - Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter